1832 Asset Management L.P. Mirati Therapeutics, Inc. Transaction History

1832 Asset Management L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $1.75 Million - $2.47 Million	-22,500 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $1.34 Million - $2.36 Million	22,500 New	22,500 $2.36 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.